Altimmune Inc ALT 深 滬
已收盤 12-05 16:00:00 美东时间
5.24
-0.070
-1.32%
華盛通- 最 高5.44
- 今 開5.31
- 成交量 258.38万股
- 最 低 5.19
- 昨 收 5.31
- 總市值 5.45亿
- 52周最高 9.59
- 市盈率 靜 --
- 換手率 2.48%
- 52周最低 2.90
- 委 比 6.93%
- 總股本 1.04亿
- 歷史最高 237.30
- 量 比 0.85
- 振 幅 4.71%
- 歷史最低 1.51
- 每 手 1
- 風險率 1.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Altimmune Announces CEO Transition and Succession Plan
Altimmune Inc. announced that Vipin Garg, Ph.D., will step down as CEO effective January 1, 2026, after seven years of leadership. Jerry Durso, the company’s chairman, will succeed him. Garg will serve as an advisor until June 2026. Durso brings over 30 years of experience in life sciences, including leading Intercept Pharmaceuticals and Sanofi. Garg’s tenure saw the advancement of pemvidutide, a dual glucagon/GLP-1 receptor agonist, into Phase 3...
12-01 12:30
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference
Altimmune, Inc. announced that its management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 2:30 p.m. ET. The session will be available via webcast on the company's website. Altimmune is a clinical-stage biotech company developing peptide-based therapies for liver and cardiometabolic diseases, with its lead candidate pemvidutide targeting metabolic dysfunction-associated st...
11-26 12:30
Altimmune releases additional phase 2 pemvidutide data for MASH
Additional data from the phase 2b trial of Altimmune's (ALT) pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH) some improvements in the liver condition over 24 weeks of treatment...
11-11 23:04
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
Celldex appointed Teri Lawver as Senior Vice President and Chief Commercial Officer. With over 30 years of experience in the biopharmaceutical and medical device sectors, Lawver succeeds Richard Wright, who is retiring after a decade at Celldex. Lawver's expertise in immunology and inflammation includes successful launches of key treatments, and she will oversee the potential launch of barzolvolimab and advance Celldex's pipeline. Wright's contri...
11-10 13:01
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Altimmune Q3 EPS $(0.21) Beats $(0.27) Estimate, Sales $5.000K Beat $1.250K Estimate
Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.27) by 22.51 percent. This is a 34.38 percent increase over losses of $(0.32) per share from the same
11-06 20:07
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Altimmune to Participate in Two Upcoming Investor Conferences
<p>Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that its management team will participate in the Stifel 2025 Healthcare Conference on November 12, 2025, and the Jefferies Global Healthcare Conference on November 20, 2025. Both events will feature fireside chats available via webcast on the company’s website. Altimmune focuses on developing peptide-based therapies for liver and cardiometabolic diseases, with its lead cand...
11-05 12:30
Altimmune Completes Patient Enrollment In RECLAIM, Phase 2 Clinical Trial Evaluating Pemvidutide In Adults With Alcohol Use Disorder
Enrollment completed ahead of schedule, underscoring strong interest from patient community in a potential new therapeutic optionOn track to complete the 24-week treatment period and announce topline results in
11-03 20:37
